Protox Initiates Phase 2 Prostate Cancer Study

Vancouver, BC, January 15, 2008--Protox Therapeutics today announced that the Company has received Institutional Review Board approvals to proceed with its Phase 2a clinical trial evaluating PRX302 after the treatment of localized . 15 /CNW/ - Protox Therapeutics Inc. (TSX-V:PRX), a leaderin the incident of targeted therapeutic proteins, today announced that theCompany has received Institutional Review Board (IRB) approvals to proceedwith its Phase 2a clinical . Vancouver, BC, January 30, 2008--Protox Therapeutics announced that it has received conditional approval after the listing of its commonplace shares on the Toronto Stock Exchange.. 15 /CNW/ - Protox Therapeutics Inc. (TSX-V:PRX), a leaderin the incident of targeted therapeutic proteins, today announced that theCompany has received Institutional Review Board (IRB) approvals to proceedwith its Phase 2a clinical . VANCOUVER - Protox Therapeutics Inc. (TSXV:PRX) has reported a positive Phase 1 study on its PRX302 drug runner after benign prostatic hyperplasia, a commonplace condition amidst aging males. Protox said Thursday that results from the trial . 15 /CNW/ - Protox Therapeutics Inc. (TSX-V:PRX), a leaderin the incident of targeted therapeutic proteins, today announced that theCompany has received Institutional Review Board (IRB) approvals to proceedwith its Phase 2a clinical . Vancouver, BC, January 15, 2008--(T-Net)--Protox Therapeutics (TSX-V:PRX), a leader in the incident of targeted therapeutic proteins, today announced that the tanning Company has received Institutional Review Board approvals to proceed with .